...
首页> 外文期刊>Bioorganic and medicinal chemistry >13,13-Dimethyl-des-C,D analogues of (20S)-1alpha,25-dihydroxy-2-methylene-19-norvitamin D (2MD): total synthesis, docking to the VDR, and biological evaluation.
【24h】

13,13-Dimethyl-des-C,D analogues of (20S)-1alpha,25-dihydroxy-2-methylene-19-norvitamin D (2MD): total synthesis, docking to the VDR, and biological evaluation.

机译:(20S)-1alpha,25-二羟基-2-亚甲基-19-诺维他命D(2MD)的13,13-二甲基-des-C,D类似物:全合成,对接VDR和生物学评估。

获取原文
获取原文并翻译 | 示例
           

摘要

As a continuation of our studies focused on the vitamin D compounds lacking the C,D-hydrindane system, 13,13-dimethyl-des-C,D analogues of (20S)-1alpha,25-dihydroxy-2-methylene-19-norvitamin D(3) (2, 2MD) were prepared by total synthesis. The known cyclohexanone 30, a precursor of the desired A-ring phosphine oxide 11, was synthesized starting with the keto acetal 13, whereas the aldehyde 12, constituting an acyclic 'upper' building block, was obtained from the isomeric esters 34, prepared previously in our laboratory. The commercial 1,4-cyclohexanedione monoethylene ketal (13) was enantioselectively alpha-hydroxylated utilizing the alpha-aminoxylation process catalyzed by l-proline, and the introduced hydroxy group was protected as a TBS, TPDPS, and SEM ether. Then the keto group in the obtained compounds 15-17 was methylenated and the allylic hydroxylation was performed with selenium dioxide and pyridine N-oxide. After separation of the isomers, the newly introduced hydroxy group was protected and the ketal group hydrolyzed to yield the corresponding protected (3R,5R)-3,5-dihydroxycyclohexanones 30-32. The esters 34, starting compounds for the C,D-fragment 12, were first alpha-methylated, then reduced and the resulted primary alcohols 36 were deoxygenated using the Barton-McCombie protocol. Primary hydroxy group in the obtained diether 38 was deprotected and oxidized to furnish the aldehyde 12. The Wittig-Horner coupling of the latter with the anion of the phosphine oxide 11, followed by hydroxyl deprotection furnished two isomeric 13,13-dimethyl-des-C,D analogues of 2MD (compounds 10 and 42) differing in configuration of their 7,8-double bond. Pure vitamin D analogues were isolated by HPLC and their biological activity was examined. The in vitro tests indicated that, compared to the analogue 7, unsubstituted at C-13, the synthesized vitamin D analogue 10 showed markedly improved VDR binding ability, significantly enhanced HL-60 differentiation activity as well as increased transcriptional potency. Docking simulations provided a rational explanation for the observed binding affinity of these ligands to the VDR. Biological in vivo tests proved that des-C,D compound 10 retained some intestinal activity. Its geometrical isomer 42 was devoid of any biological activity.
机译:作为我们研究的继续,重点是缺乏C,D-茚满系统的维生素D化合物,(20S)-1α,25-二羟基-2-亚甲基-19-的13,13-二甲基-des-C,D类似物通过全合成制备了维生素D(3)(2,2MD)。从酮缩醛13开始合成了已知的环己酮30(所需的A环氧化膦11的前体),而醛12则由先前制备的异构酯34构成无环“上部”结构单元的醛12在我们的实验室。利用1-脯氨酸催化的α-氨基羟甲基化过程,将商品化的1,4-环己二酮单乙烯缩酮(13)对映体选择性地α-羟基化,并将引入的羟基保护为TPS,TPDPS和SEM醚。然后,将获得的化合物15-17中的酮基甲基化,并用二氧化硒和吡啶N-氧化物进行烯丙基羟基化。分离异构体后,将新引入的羟基保护,并将缩酮水解,得到相应的被保护的(3R,5R)-3,5-二羟基环己酮30-32。首先将C,D片段12的起始化合物酯34进行α-甲基化,然后还原,然后使用Barton-McCombie规程将所得的伯醇36脱氧。将获得的二醚38中的伯羟基脱保护并氧化以提供醛12。后者的Wittig-Horner偶联与氧化膦11的阴离子,随后进行羟基脱保护,得到两个异构体13,13-二甲基-des- 2MD的C,D类似物(化合物10和42)的7,8双键构型不同。通过HPLC分离纯的维生素D类似物,并检查其生物学活性。体外试验表明,与在C-13处未取代的类似物7相比,合成的维生素D类似物10的VDR结合能力显着提高,HL-60分化活性显着增强,转录能力增强。对接模拟为观察到的这些配体对VDR的结合亲和力提供了合理的解释。体内生物学测试证明des-C,D化合物10保留了一定的肠道活性。其几何异构体42没有任何生物活性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号